ArticleJournal of neuro-oncology2026
Multiomics integration of serum proteome and autoantibody profiles reveals diagnostic and prognostic biomarkers in glioma.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundGlioma is the most aggressive primary brain tumor with glioblastoma (GBM, IDH-wildtype) as its most malignant subtype, and is associated with a dismal prognosis, creating an urgent need for noninvasive biomarkers to enable early detection and prognostic stratification. Single-marker detection exhibits inherent limitations in clinical practice, whereas multi-marker panels hold greater promise for enhancing diagnostic efficacy.
methodsTandem mass tag (TMT)-based quantitative proteomics was performed on sera from 30 glioma patients and 30 matched healthy controls (HCs) to identify differentially expressed proteins (DEPs). Candidate tumor-associated antigens were used to design a custom peptide microarray assessing IgG/IgM autoantibodies in the discovery (n = 55 glioma patients, 30 HCs) and validation (n = 32 glioma patients, 29 HCs) cohorts. Prognostic value was analyzed via Kaplan–Meier and Cox regression, and findings were integrated with TCGA transcriptomics and single-cell RNA sequencing data to determine immune associations and cellular origins. Subgroup analysis by IDH status was performed for GBM IDH-wildtype cohort to verify subtype-specific biomarker potential.
resultsProteomics identified 877 proteins, with DEPs enriched in extracellular matrix remodeling, complement/coagulation cascades, and metabolism/oxidative stress pathways. A three-IgM panel (anti-p-APOE-1, anti-p-P53-1, and anti-p-SAA4-1) showed high diagnostic performance (AUC = 0.96; 0.80 validation). In the GBM IDH-wildtype subgroup, IgG-p-P53-1 and IgM-p-P53-1 were significantly highly expressed in the training set and validation set (P < 0.05), while IgM-p-APOE-1 showed moderate diagnostic efficacy in the training set (AUC = 0.776) but poor generalization in the validation set (AUC = 0.483). IgM-p-SAA4-1 positivity was an independent protective factor for longer survival in pan-glioma patients(P = 0.010). APOE and IL1B are expressed predominantly by tumor-associated macrophages, with divergent prognostic implications at the transcript level.
conclusionIntegrated proteomic–autoantibody profiling identified and validated a serum IgM panel with robust pan-glioma diagnostic accuracy and prognostic relevance in glioma. The three-IgM panel shows pan-glioma diagnostic value, while GBM IDH-wildtype subtype-specific biomarkers require further verification with expanded sample size. These biomarkers reflect interactions between humoral immunity, tumor gene expression, and the immune microenvironment, supporting their potential for clinical translation in glioma early detection and personalized patient stratification.
Indexed as
Identifiers
41701384What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.